A Novel Gene Signature Associated with Inflammatory Responses and Immune Status Assists in Prognosis and Intervention for Patients with HCC.
Guofang LuRui DuBin FengJianlin WangFengrui ZhangJianming PeiZhaoyang WangYulong ShangPublished in: Journal of inflammation research (2022)
The inflammatory-response-associated gene signature could predict the prognosis and the immunological status of HCC patients. Additionally, bleomycin, simvastatin and zoledronate may represent potential drug candidates that could inhibit these genes. This may constitute a new approach for the treatment of HCC.
Keyphrases
- inflammatory response
- genome wide
- end stage renal disease
- genome wide identification
- copy number
- randomized controlled trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- transcription factor
- gene expression
- patient reported outcomes
- toll like receptor
- combination therapy
- drug induced
- patient reported